(Q43828455)

27 November 2017

title

The role of Certican (everolimus, rad) in the many pathways of chronic rejection (English)

1 reference

27 November 2017

B Nashan

1

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 November 2001

1 reference

Transplantation Proceedings

27 November 2017

published in

1 reference

27 November 2017

volume

33

1 reference

27 November 2017

issue

7-8

1 reference

27 November 2017

page(s)

3215-3220

1 reference

Chronic allograft nephropathy: An update

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

SDZ RAD, a new rapamycin derivative: synergism with cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

The macrolide SDZ RAD is efficacious in a nonhuman primate model of allotransplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

Combined immunosuppression with cyclosporine (neoral) and SDZ RAD in non-human primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerability.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

Successful treatment of acute, ongoing rat lung allograft rejection with the novel immunosuppressant SDZ-RAD.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

Increased impact of acute rejection on chronic allograft failure in recent era.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

Clinical determinants of multiple acute rejection episodes in kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

Features of acute rejection that increase risk for chronic rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

Chronic allograft failure in human renal transplantation: a multivariate risk factor analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

The impact of acute rejection on chronic rejection: a report of the North American Pediatric Renal Transplant Cooperative Study

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

Neoral use in the renal transplant recipient

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

Impact of acute rejection on development of chronic rejection in pediatric renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

Cyclosporin A withdrawal in live related renal transplantation: long-term results

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

A BLINDED, LONG-TERM, RANDOMIZED MULTICENTER STUDY OF MYCOPHENOLATE MOFETIL IN CADAVERIC RENAL TRANSPLANTATION

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

Cytomegalovirus infection and graft rejection in renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

Quantitation of allograft fibrosis and chronic allograft nephropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

Prevention of small airway obliteration in a swine heterotopic lung allograft model.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

SDZ RAD inhibits cold ischemia-induced vascular remodeling

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

The clinical impact of nephrotoxicity in renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902369-7

7 January 2021

10.1016/S0041-1345(01)02369-7

Identifiers

DOI

1 reference

27 November 2017

1 reference